Insider · CIK 0001551966

Hopfner Robert Lorne

Reports to the SEC for 5 companies · EAST BERLIN, CT

sec.gov

Transactions

Companies

Filings

CIK

0001551966

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-12	RLYBRallybio CorpM Exercise/Conversion	Director	MExercise/Conversion	+2,062 sh	$15.28	+$31.5K	14,820
2026-10-12	RLYBRallybio CorpM Exercise/Conversion	Director	MExercise/Conversion	+9,196 sh	$7.60	+$69.9K	9,196
2026-10-12	RLYBRallybio CorpM Exercise/Conversion	Director	MExercise/Conversion	+3,562 sh	$2.38	+$8,477.56	12,758
2026-10-12	RLYBRallybio Corp · Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,062 sh	—	—	0
2026-10-12	RLYBRallybio Corp · Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,196 sh	$0.56	−$5,149.76	0
2026-10-12	RLYBRallybio Corp · Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,562 sh	—	—	0
2025-12-19	EVMNEvommune, Inc.P Purchase	Director, 10% Owner	PPurchase	+1,000 sh	$17.35	+$17.4K	4,026
2025-11-07	EVMNEvommune, Inc.C Conversion	Director, 10% Owner	CConversion	+1.44M sh	—	—	1,441,032
2025-11-07	EVMNEvommune, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.51M sh	—	—	0
2025-11-07	EVMNEvommune, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−314K sh	—	—	0
2025-11-07	EVMNEvommune, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−314K sh	—	—	0
2025-11-07	EVMNEvommune, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.1M sh	—	—	0
2025-11-07	EVMNEvommune, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.9M sh	—	—	0
2025-11-07	EVMNEvommune, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−7.23M sh	—	—	0
2025-11-07	EVMNEvommune, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.58M sh	—	—	0
2025-11-07	EVMNEvommune, Inc. · Series Seed Preferred StockC Conversion	Director, 10% Owner	CConversion	−3.57M sh	—	—	0
2025-11-07	EVMNEvommune, Inc. · Series Seed Preferred StockC Conversion	Director, 10% Owner	CConversion	−7.15M sh	—	—	0
2025-11-07	EVMNEvommune, Inc. · Series Seed Preferred StockC Conversion	Director, 10% Owner	CConversion	−25.8K sh	—	—	0
2025-11-07	EVMNEvommune, Inc.C Conversion	Director, 10% Owner	CConversion	+295K sh	—	—	294,502
2025-11-07	EVMNEvommune, Inc.C Conversion	Director, 10% Owner	CConversion	+1.63M sh	—	—	1,632,441
2025-11-07	EVMNEvommune, Inc.C Conversion	Director, 10% Owner	CConversion	+3,026 sh	—	—	3,026
2025-07-01	Inozyme Pharma, Inc.U Disposition from Tender	Director	UDisposition from Tender	−1.57M sh	$4.00	−$6.29M	0
2025-07-01	Inozyme Pharma, Inc.U Disposition from Tender	Director	UDisposition from Tender	−2.92M sh	$4.00	−$11.7M	0
2025-05-13	RLYBRallybio Corp · Option (Right to Buy)A Award	Director	AAward	+28.5K sh	—	—	28,500
2025-01-02	RLYBRallybio Corp · Option (Right to Buy)A Award	Director	AAward	+73.6K sh	$0.70	+$51.5K	73,571
2024-06-18	Inozyme Pharma, Inc.Stock Option (right to buy)A Award	Director	AAward	+28K sh	—	—	28,000
2024-05-15	RLYBRallybio Corp · Option (Right to Buy)A Award	Director	AAward	+16.5K sh	—	—	16,500
2023-08-01	Inozyme Pharma, Inc.P Purchase	Director	PPurchase	+714K sh	$4.80	+$3.43M	1,571,741
2023-08-01	Inozyme Pharma, Inc.P Purchase	Director	PPurchase	+119K sh	$4.80	+$571K	2,923,110
2023-06-13	Inozyme Pharma, Inc.Stock Option (right to buy)A Award	Director	AAward	+16K sh	—	—	16,000
2023-05-17	RLYBRallybio Corp · Option (Right to Buy)A Award	Director	AAward	+15.5K sh	—	—	15,490
2023-05-12	Inozyme Pharma, Inc.P Purchase	Director	PPurchase	+229K sh	$6.25	+$1.43M	3,661,518
2023-05-11	Inozyme Pharma, Inc.P Purchase	Director	PPurchase	+219K sh	$6.48	+$1.42M	3,432,816
2023-03-29	Inozyme Pharma, Inc.P Purchase	Director	PPurchase	+345K sh	$4.54	+$1.56M	3,213,586
2023-03-28	Inozyme Pharma, Inc.P Purchase	Director	PPurchase	+157K sh	$4.16	+$652K	2,868,994
2023-03-27	Inozyme Pharma, Inc.P Purchase	Director	PPurchase	+51.1K sh	$3.70	+$189K	2,712,228
2022-06-10	Inozyme Pharma, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+9,367 sh	—	—	9,367
2022-05-24	RLYBRallybio Corp · Option (Right to Buy)A Award	Director	AAward	+13.4K sh	—	—	13,440
2022-04-19	Inozyme Pharma, Inc.P Purchase	Director	PPurchase	+1.07M sh	$3.69	+$3.95M	2,661,154
2022-01-03	RLYBRallybio Corp · Option (Right to Buy)A Award	Director	AAward	+6,242 sh	—	—	6,242
2021-08-02	RLYBRallybio CorpP Purchase	Director	PPurchase	+577K sh	$13.00	+$7.5M	2,267,411
2021-07-28	RLYBRallybio Corp · Option (Right to Buy)A Award	Director	AAward	+13.4K sh	—	—	13,440
2021-07-28	RLYBRallybio CorpJ Other	Director	JOther	+1.69M sh	—	—	1,694,388
2021-07-28	RLYBRallybio Corp · Series B Preferred UnitsJ Other	Director	JOther	−10.8M sh	—	—	0
2021-06-23	Inozyme Pharma, Inc.Stock Option (right to buy)A Award	Director	AAward	+9,367 sh	—	—	9,367
2021-06-02	PCVXVaxcyte, Inc. · Stock Option (right to buy)A Award	Director	AAward	−15K sh	—	—	15,000
2021-02-10	PCVXVaxcyte, Inc.S Sale	Director	SSale	−6,632 sh	$28.66	−$190K	1,405,418
2021-02-10	PCVXVaxcyte, Inc.S Sale	Director	SSale	−37.3K sh	$25.75	−$960K	1,446,305
2021-02-10	PCVXVaxcyte, Inc.S Sale	Director	SSale	−26.7K sh	$26.78	−$715K	1,419,617
2021-02-10	PCVXVaxcyte, Inc.S Sale	Director	SSale	−7,567 sh	$27.64	−$209K	1,412,050

Recent filings

Accepted (ET)
Oct 14 16:344
Hopfner Robert Lorne0001193125-26-421747
SEC(opens sec.gov)
Dec 224
Hopfner Robert Lorne0001012975-25-000937
SEC(opens sec.gov)
Nov 124
Hopfner Robert Lorne0001551966-25-000007
SEC(opens sec.gov)

Companies

Address

C/O RALLYBIO CORPORATION PO BOX 325

EAST BERLIN, CT, 06023